Literature DB >> 2029798

Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium.

H Kimata1, A Yoshida, C Ishioka, H Mikawa.   

Abstract

The effect of recombinant human erythropoietin (Epo) on plasma cells was studied in a serum-free medium, COSMEDIUM-001 (Cosmedium). Epo enhanced both Ig production and thymidine uptake by human plasma cell lines, AF-10 and IM-9. Interleukin-6 (IL-6) enhanced both Ig production and thymidine uptake by AF-10 and IM-9, while other cytokines, including IL-1 beta, IL-2, IL-3, IL-4, IL-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-alpha (IFN-alpha) or IFN-gamma, failed to do so. However, the Epo effect was specific since Epo-induced enhancement of Ig production and thymidine uptake was blocked by the anti-Epo antibody but not by the anti-IL-6 antibody or the control antibody. Conversely, IL-6-induced enhancement was blocked by the anti-IL-6 antibody but not by the anti-Epo antibody. Epo also enhanced Ig production (IgG, IgM, and IgA) and thymidine uptake by PCA-1+ plasma cells generated in vitro. This enhancement was also blocked by the anti-Epo antibody but not by the anti-IL-6 antibody. Taken together, these results suggest that Epo enhances plasma cell responses by a different mechanism than does IL-6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029798     DOI: 10.1016/0090-1229(91)90044-b

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

1.  Secretory IgA in saliva can be a useful stress marker.

Authors:  S Tsujita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1999-04       Impact factor: 3.674

Review 2.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

3.  Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

Authors:  F Silvestris; A Romito; P Fanelli; A Vacca; F Dammacco
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.